BioSpecifics Technologies Corp. is a profitable, commercial-stage biopharmaceutical company that has developed injectable collagenase for twelve clinical indications to date. Injectable collagenase is approved for marketing as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. for the treatment of adult Dupuytren's contracture patients with up to two palpable cords in the same palm and for Peyronie's disease in men with a palpable plaque and a curvature of 30 degrees or greater at the start of therapy. XIAFLEX is also approved in Canada & Australia for Dupuytren's contracture and
XIAPEX® (the EU tradename for CCH) is marketed in the EU for both Dupuytren's contracture and Peyronie's disease.

BioSpecifics' strategic partner, Endo International plc (Endo), markets XIAFLEX for Dupuytren's contracture and Peyronie's disease and is also managing the research and development of CCH for their licensed indications. Ex-U.S partnerships include Actelion Pharmaceuticals Ltd. in Canada, Australia, Brazil and Mexico, Asahi Kasei Pharma Corporation in Japan and Swedish Orphan Biovitrum AB in 71 Eurasian and African countries.

Patient Discussion Forums

Forums are designed to enable patients and others concerned to interact with each other. Discussions on virtually any aspect of lipoma and Peyronie's disease are acceptable, however, please abide by the guidelines.